US institution changes share price target for three big Danish drugmakers
Three of Denmark’s biggest life science firms, Novo Nordisk, Lundbeck and Genmab, have had their share price target adjusted by a private wealth manager in the US.
by marketwire, translated by daniel pedersen
US-based private wealth manager Bernstein has taken stock of three large Danish drugmakers – Novo Nordisk, Lundbeck and Genmab – resulting in share price target changes for all three, Bloomberg News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Cancer drug hope raises Genmab's spirits after legal defeat
For subscribers
Novo Nordisk target price increased by five institutions
For subscribers
.jpg&w=384&q=75)
